C4 Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGC4 Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings growth of 82% provides fundamental context to the price action. However, with RSI at 76, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.07 | +30.61% | ABOVE |
| 50 SMA | $2.09 | +29.33% | ABOVE |
| 100 SMA | $2.27 | +19.14% | ABOVE |
| 150 SMA | $2.35 | +14.83% | ABOVE |
| 200 SMA | $2.18 | +23.83% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CCCC in an uptrend right now?
CCCC has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CCCC overbought or oversold?
CCCC's RSI (14) is 76. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is CCCC outperforming the market?
CCCC has a Relative Strength (RS) Rating of 83 out of 99. Yes, CCCC is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is CCCC in its 52-week range?
CCCC is trading at $2.70, which is 74% of its 52-week high ($3.65) and 63% above its 52-week low ($1.09).
How volatile is CCCC?
CCCC has a Beta of 1.55 and 52-week volatility of 102%. It's more volatile than the S&P 500 - expect bigger swings.